PF-Atlas › Clinical Trials › NCT02514473

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

VX-809 · Phase 3

Registry ID

NCT02514473

Phase

Phase 3

Status

Completed

Drug / intervention

VX-809

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2015-07

About this trial

VX-809 is evaluated in NCT02514473, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.

View NCT02514473 on ClinicalTrials.gov →

Explore related

All VX-809 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02514473 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.